Please assess the completion status of the following clinical trial:

Trial Title: Research Investigation of Soy and Estrogen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Female~* Perimenopausal as defined by the Stages of Reproductive Aging Workshop (STRAW) criteria, specifically in either of the two following stages: a) early transition defined as changes in cycle length of seven days or more in either direction in consecutive cycles or b) late transition defined as \> 60 days amenorrhea and FSH \> 40 IU/mL~* Intact uterus/ovaries (i.e. no surgical menopause)~* at least 1 self-reported hot flash per week~* Estrogen therapy not contraindicated~* Able to give informed consent~* Age between 40 and 65 years~* English as first and primary language~Exclusion Criteria:~* Positive pregnancy test or breastfeeding (pregnancy tests will be given to all women)~* Obesity \> 35 BMI~* Previous history of endometrial hyperplasia/neoplasia~* Previous history of cancers of the breast or reproductive tract~* History of presence of myocardial infarction (MI) or stroke~* Current clinical diagnosis or a diagnosis within the past year of an anxiety disorder, severe recurrent depression, or severe psychiatric disturbance~* History of head injury with more than 60 minutes loss of consciousness~* History of neurological condition affecting cognitive function (e.g., brain tumor, multiple sclerosis)~* History of developmental disability affecting cognitive function (e.g., mental retardation, attention deficit)~* Current use of CNS-acting medication (e.g., antidepressants, anxiolytics, diphenhydramine)~* History or presence of cerebrovascular accident, sickle cell anemia~* History of alcohol or drug abuse as defined by DSM criteria~* Abnormal vaginal bleeding of undetermined cause~* Untreated or uncontrolled hypertension defined as systolic blood pressure greater than 165 mm hg or diastolic blood pressure greater than 95 mm hg~* Concurrent administration of medication containing estrogen, progestin, SERM within four months of enrollment~* Concurrent administration of medication containing St. John's wort, bisphosphonates, or dietary phytoestrogens within one month of enrollment~* History of migraine associated with hormone use~* History or presence of deep vein thrombosis, thrombophlebitis or thromboembolic disorder~* Current participation in any other clinical trial within 30 days of enrollment~* Smoker~* Diabetes~* Premature ovarian failure (defined as having last menstrual period before age 40)~* Abnormal PAP smear in previous year~* Abnormal mammogram in previous year~* Vegans (vegetarians who tend to consume greater than average doses of phytoestrogens)~* Allergy to soy (affects \~1% of people in the United States; reactions are typically mild)~* Symptomatic fibroids (significant size or significant menstrual changes)~* Menorrhagia~* Lactose intolerant

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Estradiol/Medroxyprogesterone Acetate (Type: EXPERIMENTAL): 1 mg/d oral Estradiol pill and 0 mg/d oral placebo pill for 12 weeks, followed by 10 mg/d oral medroxyprogesterone acetate (MPA) pill, for 10 days.
- Soy Phytoestrogen (Type: EXPERIMENTAL): 55 mg/twice daily oral Novasoy®/Soy Phytoestrogen pill for 12 weeks, followed by 0 mg/d oral placebo pill, for 10 days.
- Placebo (Type: PLACEBO_COMPARATOR): 0 mg tablet/twice daily oral placebo pill for 12 weeks, followed by 0 mg/d oral placebo pill, for 10 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).